SiBone (SIBN)
(Delayed Data from NSDQ)
$16.55 USD
+1.65 (11.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.55 USD
+1.65 (11.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.52 -0.03 (-0.18%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum C VGM
Zacks News
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Si-Bone (SIBN) Have the Potential to Rally 42% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 50%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Si-Bone (SIBN) points to a 49.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of -10.20% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of -20.93% and 0.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 12.50% and 13.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 11.71% and 2.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Si-Bone (SIBN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of -17.07% and -1.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Si-Bone (SIBN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of -7.69% and 0.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 2.63% and 7.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 6.67% and 0.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Si-Bone (SIBN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: SI-BONE
by Zacks Equity Research
SI-BONE is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 31.25% and 48.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Si-Bone (SIBN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of -30.56% and -6.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.